Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $780.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective hoisted by Truist Financial from $772.00 to $780.00 in a research report released on Wednesday,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently weighed in on REGN. Leerink Partners raised their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research report on Monday, August 17th. HSBC boosted their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Argus upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective for the company in a report on Thursday, October 1st. Finally, Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $834.24.

Regeneron Pharmaceuticals Trading Up 0.9%

NASDAQ REGN opened at $746.54 on Wednesday. Regeneron Pharmaceuticals has a 52 week low of $541.00 and a 52 week high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The stock’s 50 day moving average price is $790.99 and its two-hundred day moving average price is $720.67. The stock has a market capitalization of $76.86 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 1.39 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period last year, the business earned $12.81 EPS. As a group, analysts anticipate that Regeneron Pharmaceuticals will post 46.21 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Insider Activity

In related news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This represents a 8.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 3,946 shares of company stock valued at $3,302,458. 6.97% of the stock is owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Orbimed Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $11,358,000. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. Contravisory Investment Management Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $6,327,000. Oxbow Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $3,342,000. Finally, Deutsche Bank AG bought a new stake in Regeneron Pharmaceuticals during the second quarter worth $323,249,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.